Wall Street Zen downgraded shares of Cibus (NASDAQ:CBUS – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a research note on Friday, September 25th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cibus has a consensus rating of “Hold” and a consensus price target of $9.00.
Get Our Latest Stock Report on CBUS
Cibus Price Performance
NASDAQ CBUS opened at $1.32 on Friday. The company has a market capitalization of $100.89 million, a PE ratio of -0.80 and a beta of 1.57. Cibus has a 1 year low of $1.09 and a 1 year high of $4.19. The company has a fifty day moving average of $1.61 and a two-hundred day moving average of $1.58.
Cibus (NASDAQ:CBUS – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.10). The firm had revenue of $0.99 million during the quarter, compared to analyst estimates of $1.70 million. Cibus had a negative net margin of 2,258.89% and a negative return on equity of 287.03%. On average, research analysts expect that Cibus will post -1.13 earnings per share for the current year.
Hedge Funds Weigh In On Cibus
Hedge funds and other institutional investors have recently bought and sold shares of the company. Weiss Asset Management LP purchased a new position in Cibus during the 1st quarter worth $1,758,000. Renaissance Technologies LLC boosted its holdings in shares of Cibus by 42.5% in the first quarter. Renaissance Technologies LLC now owns 98,900 shares of the company’s stock valued at $196,000 after acquiring an additional 29,500 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Cibus by 324.2% during the first quarter. Bank of America Corp DE now owns 74,358 shares of the company’s stock worth $147,000 after acquiring an additional 56,830 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in shares of Cibus during the first quarter worth about $66,000. Finally, Rockland Trust Co. acquired a new stake in Cibus in the second quarter valued at about $41,000. 33.81% of the stock is currently owned by hedge funds and other institutional investors.
Cibus Company Profile
Cibus, Inc is an agricultural biotechnology company focused on developing and commercializing gene-edited traits for major crops. Its technology is designed to make precise changes to a plant’s existing genes without introducing foreign DNA, supporting the development of improved crop varieties through a process intended to resemble conventional breeding.
The company’s product development programs target traits such as herbicide tolerance, disease resistance, improved yield, and other characteristics intended to benefit farmers, seed companies, and the broader food and agriculture supply chain.
Featured Articles
- Five stocks we like better than Cibus
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.
